The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

NCT03951623 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG: HMPL-523
DRUG: Placebo

Sponsor

Hutchison Medipharma Limited